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D urable responses in metastatic cancers have been achieved with a variety of immunotherapies such as interleukin-2, adoptive cell transfer of tumor-infiltrating lymphocytes, antibodies that block cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), [1] [2] [3] [4] [5] and antibodies that block programmed death 1 (PD-1). [6] [7] [8] [9] [10] However, in a recent study, approximately 25% of patients with melanoma who had had an objective response to PD-1 blockade therapy had disease progression at a median follow-up of 21 months. 11 The mechanisms of immune-resistant cancer progression are mostly unknown. Previous studies involving humans examined the loss of beta-2-microglobulin as a mechanism of acquired resistance to several forms of cancer immunotherapy. [12] [13] [14] In preclinical models, defects in the interferon signaling pathway have been proposed as a potential mechanism of cancer escape (insensitivity) to immunotherapy. 15, 16 In the current study, we assessed the effect of anti-PD-1 therapy on cancer genomic evolution, including acquired mutations in the genes affecting the interferon pathway and antigen-presentation pathway, in an effort to determine genetic mechanisms of acquired resistance to PD-1 blockade therapy.
Me thods

Patients, Response Assessment, and Tumor Biopsies
Of 78 patients with metastatic melanoma who were treated with the anti-PD-1 antibody pembrolizumab at the University of California, Los Angeles (UCLA), 42 had an objective response, of whom 15 went on to have disease progression. Four of these 15 patients met all three selection criteria for this analysis. First, they must have had an objective tumor response while participating in a clinical trial with single-agent pembrolizumab. 6, 7, 10, 11 Tumor responses were evaluated at 12 weeks and confirmed 4 weeks later, and patients were assessed by imaging every 12 weeks thereafter with the use of both the Response Evaluation Criteria in Solid Tumors 17 and the immune-related response criteria. 18 Second, patients had to have late acquired resistance, defined as in situ recurrence or new lesion development, despite continuous dosing, after more than 6 months of tumor response. Third, patients had to have adequate biopsy material for wholeexome sequencing at two time points: before the initiation of pembrolizumab therapy and after disease progression. We processed tumor biopsy samples as described previously to perform pathological analyses, obtain DNA and RNA, and attempt to establish cell lines. 19, 20 Immunohistochemical, Immunofluorescence, Western Blot, and Flow-Cytometric Analyses
Immunohistochemical and immunofluorescence analyses 19 as well as Western blot and flow-cytometric analyses 21 were performed and analyzed as described previously. Full methods are included in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Genetic and Transcriptional-Profiling Analyses
Whole-exome sequencing was performed at the UCLA Clinical Microarray Core with the use of the NimbleGen SeqCap EZ Human Exome Library, version 3.0 (Roche). Mutation calling was performed as described previously. 22 Selected geneexpression profiling on interferon exposure was performed with the use of nCounter (NanoString Technologies). Whole-exome sequencing data have been deposited in the National Center for Biotechnology Information Sequence Read Archive under the accession number SRP076315.
Functional Studies
Patient-derived and previously established human melanoma cell lines were used to analyze recognition by T-cell receptor transgenic T cells 23 with the use of in vitro coculture assays that detect antigen-induced release of interferon-γ assessed by enzyme-linked immunosorbent assay. Cellproliferation and growth-inhibition assays were performed with the use of an automated live-cell imaging system (IncuCyte, Essen BioScience) with or without exposure to interferons. Full methods are described in the Supplementary Appendix.
Study Oversight
Data generated and collected by the study investigators were analyzed by the last author, who vouches for the completeness and accuracy of the data, analyses, and reported results. Summaries of the clinical protocol have been reported by Hamid et al. 6 and Robert et al.
Student's t-test and a two-way analysis of variance were used for cell-culture experiments, with Dunnett's correction applied for multiple comparisons with untreated controls.
R esult s
Clinical Course and Immune Infiltrates
We analyzed paired tumor samples from four (nonconsecutive) selected patients with metastatic melanoma who had had a relapse while receiving PD-1-inhibition therapy with pembrolizumab (Tables S1 and S2 in the Supplementary Appendix). All four patients met objective criteria for a partial response, 17, 18 though with slightly different kinetics (Fig. 1, and Figs. S1, S2, and S3 in the Supplementary Appendix). The mean time to relapse was 624 days (range, 419 to 888). The baseline biopsy samples were obtained just before the initiation of pembrolizumab therapy in Patients 2, 3, and 4, whereas for Patient 1, the only available baseline biopsy sample was obtained before an earlier course of therapy with the BRAF inhibitor vemurafenib. The baseline biopsy samples from Patients 1, 2, and 3 showed preexisting CD8 T-cell infiltrates at the invasive margin that colocalized with programmed death ligand 1 (PD-L1) expression on surrounding macrophages and melanoma cells (Fig. 1B, and Figs. S1B and S2B in the Supplementary Appendix). The biopsy samples obtained at the time of response in Patients 2, 3, and 4 showed a marked increase in intratumoral CD8 T-cell in- In Panel A, computed tomographic images show a melanoma small-bowel metastasis at baseline, at the time of maximum response, and at the time of an in situ relapse after a year of minimal residual disease; the red dots in the graph on the right indicate these three time points. Immunohistochemical staining and multiplexed immunofluorescence analysis showed abundant CD8 T-cell infiltrates and programmed death ligand 1 (PD-L1) expression at baseline and again at the time of relapse at the tumor margin in Panels B and C, respectively. In the immunofluorescence images, red indicates PD-L1, yellow CD8 T cells, light blue the melanoma marker S100 (cytoplasmic staining), and dark blue the melanoma marker Sox10 (nuclear staining). were negative for PD-L1 even when directly adjacent to T cells, whereas macrophages and stromal cells were positive for PD-L1.
A Metastatic Lesion at
Genetic Changes in Relapse Biopsy Samples
The pattern of a strong initial response, long dormancy, and rapid late progression led us to hypothesize that relapse in these patients resulted from immune-mediated clonal selection and tumor outgrowth. 24 To identify mutations that might confer immune resistance, we extracted DNA from bulk-tumor biopsy samples or early-passage primary cell lines (Table S2 in the Supplementary Appendix) and performed wholeexome sequencing to compare baseline and matched relapsed tissues. We achieved a median coverage of 149×, and the percent of tumor cells (as compared with stromal cells) was more than 40% in all samples (Table S2 in the Supplementary Appendix). Nonsynonymous mutations for all samples are shown in Table S4 in the Supplementary Appendix.
JAK Mutations with Concurrent Loss of Heterozygosity at Relapse
We found strong evidence that the relapsed tumors were closely genetically related to their baseline counterparts, despite up to 2 years between biopsies. In the case of Patients 1 and 2, of 1173 and 240 nonsynonymous mutations, respectively, originally identified in the baseline sample, 92.5% and 95.8% were also seen in the resistant tumor ( Fig. 2A , and Fig. S4 in the Supplementary Appendix). The relapsing tumors also contained the same chromosomal loss-ofheterozygosity events as the baseline tumors, and all differences were due to further loss in the relapse samples. In the relapse biopsy samples from both patients, we identified new homozygous loss-of-function mutations in the kinases associated with the interferon-receptor pathway, with a Q503* nonsense mutation in the gene encoding Janus kinase 1 (JAK1) in Patient 1 ( Fig The JAK2 mutation was the only homozygous mutation (adjusted variant allele frequency, >85%) of 76 new nonsynonymous mutations in Patient 2, and the JAK1 mutation was 1 of only 3 homozygous mutations among 53 new mutations in Patient 1 (Table S5 in the Supplementary Appendix). To become homozygous, both JAK mutations were acquired in the context of a copynumber-neutral nondisjunction event, resulting in loss of the wild-type chromosome and duplication of the mutated allele. This is seen clearly in Patient 1: at relapse, chromosome 1p (containing JAK1) showed a decrease in minor-allele frequencies for germline single-nucleotide polymorphisms relative to baseline ( In Panel A, a Circos plot 25 of Patient 1 shows differences in whole-exome sequencing between the pre-pembrolizumab and post-relapse biopsies. The red circle highlights a new, high-allele-frequency, relapse-specific mutation in the gene encoding Janus kinase 1 ( JAK1) in the context of chromosomal loss of heterozygosity (asterisk). Each wedge represents a chromosome. In the outer track (black background), each point represents a nonsynonymous mutation, with most detected in both biopsy samples (gray) rather than at relapse only (red) or baseline only (green). The y-axis position indicates the variant allele frequency (VAF) at relapse, unless baseline-specific. The middle and inner tracks show copy-number status for the baseline and relapse biopsy, respectively; dark green in the subtrack indicates loss of heterozygosity. In Panel B, Integrative Genomics Viewer (IGV) plots (top) show that the JAK1 Q503* nonsense mutation is relapse-specific, and the cBioPortal Supplementary Appendix), was missing 36 heterozygous baseline mutations (presumably on the lost allele), and contained 20 mutations (presumably on the amplified allele) that became homozygous (adjusted variant allele frequency, >85%, with change of >35 percentage points from baseline). A similar loss-of-heterozygosity event occurred for chromosome 9 in Patient 2 ( Fig. S8 and Table S5 in the Supplementary Appendix).
Together, these data suggest that the tumors resistant to anti-PD-1 are a relatively homogenous population derived directly from the baseline tumor and that acquisition of the JAK mutations was an early founder event before clonal selection and relapse despite the fact that the mutation was not detected in pretreatment tumor tissue.
Functional Effects of JAK2 Mutation
To assess the functional consequences of the observed JAK mutations, we focused on the JAK2 mutation from Patient 2 using two cell lines established at baseline (M420, wild-type JAK2) and at the time of relapse (M464, JAK2 F547 splicesite mutation). Whole-exome sequencing confirmed that the original bulk tumor was well represented by M464 (Fig. S9 in the Supplementary Appendix). Western blot analysis showed that the baseline cell line responded to interferon alfa, beta, and gamma with the expected signal transduction, including an increase in signal transducer and activator of transcription 1 (STAT1) and interferon regulatory factor (IRF) expression, STAT1 phosphorylation (pSTAT1), and the production of downstream interferon targets such as PD-L1, transporter associated with antigen processing 1 (TAP1), and major histocompatibility complex (MHC) class I (Fig. 3A) . However, the cell line from the progressing lesion showed a total loss of JAK2 protein (Fig. 3A) , resulting in a lack of response to interferon gamma, without change in sensitivity to interferon alfa or beta. This was true of the pSTAT1 response (Fig. 3A) and the expression of PD-L1 and MHC class I molecules ( Fig. 3A and 3B ). The progressing cell line also failed to up-regulate a wider panel of interferon-induced transcripts involved in antigen presentation and T-cell chemotaxis (Fig. 3C , and Table S6 in the Supplementary Appendix). Together, these data indicate a total loss of functional response to interferon gamma and are consistent with JAK2 being required for signaling through the interferon-γ receptor, as opposed to the interferon-α/β receptor, which uses TYK2 and JAK1.
27-29
Loss of Interferon Gamma-Induced Growth Arrest through Acquired JAK Mutations
We hypothesized that inactivating JAK mutations may result in a functional advantage for the progressive tumors because the lack of interferon signaling either decreased antigen presentation or allowed escape from interferon-induced inhibition of growth. In addition to using M420 and M464, we engineered the human melanoma cell line M407 by means of the CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 approach to create sublines without expression of JAK1 or JAK2 (Figs. S10 and S11 in the Supplementary Appendix). These created truncating mutations analogous to those from Patients 1 and 2, and M407 is positive for HLA-A*02:01 and expresses the cancer-testis antigen NY-ESO-1, which allowed us to model T-cell recognition using T cells genetically modified to express an NY-ESO-1-specific T-cell receptor. 23 M407 and both JAK-loss sublines were equally recognized by NY-ESO-1-specific T cells, leading to high levels of interferon-γ production (Fig. 4A) .
When cultured in recombinant interferon alfa, beta, or gamma, the M420 and M407 parental cell lines showed interferon-induced growth inhibition in a dose-dependent manner (Fig. S12 in the Supplementary Appendix). However, both the JAK2-deficient M464 cell line (from Patient 2 at relapse) and the M407 JAK2-knockout subline were insensitive specifically to interferon gammainduced growth arrest, yet remained sensitive to type I interferons alfa and beta; in contrast, the M407 JAK1-mutated subline was resistant to all three interferons (Fig. 4B) . This is again consistent with the specific association of JAK2 with the interferon-γ receptor and the common use of JAK1 by all three interferon receptors. [27] [28] [29] As an orthogonal test of these effects, we treated our cell lines with 2′3′-cGAMP (cyclic guanosine monophosphate-adenosine monophosphate); this dinucleotide, which is produced in response to and STAT3 or to up-regulate interferon-response targets TAP1, PD-L1, and major histocompatibility complex (MHC) class I after treatment specifically with interferon gamma (red box), as compared with intact signaling in M420 (blue box). There was no change in response to interferon alfa or beta. As shown in Panel B, a lack of response to interferon gamma exposure was also seen in surface staining for PD-L1 and MHC class I by flow cytometry. Each point represents an independent experiment, T bars represent standard deviations, and P values are for a two-way analysis of variance with Dunnett's correction. MFI denotes mean fluorescent intensity, and NS not significant. Panel C shows log 2 RNA counts of expression for 790 immune-related genes on exposure to interferon gamma or vehicle control. The baseline cell line M420 (top) showed up-regulation of many interferon-stimulated genes (line represents an increase by a factor of 4), whereas the JAK2 mutated progression cell line M464 (bottom) lacked a similar response. cytosolic double-stranded DNA, directly activates the stimulator of interferon genes (STING) and leads to interferon-β production through activation of interferon regulatory factor 3 (IRF-3).
30
After 2′3′-cGAMP treatment, we observed growth arrest in all cell lines independent of JAK2 status but no effect in the JAK1-knockout subline (Fig.  4C) . Therefore, the JAK1 and JAK2 loss-of-function mutations did not decrease in vitro T-cell recognition but selectively blocked the interferon-γ signaling that leads to cell-growth inhibition, which for JAK2 loss could be corrected by type I pathway activation or a STING agonist.
Functional Effects of Mutation in the Gene Encoding Beta-2-Microglobulin (B2M)
In Patient 3, whole-exome sequencing of the baseline and progressive lesions showed a 4-bp S14 frame-shift deletion in exon 1 of the beta-2-microglobulin component of MHC class I as 1 of only 24 new relapse-specific mutations and the only such mutation that was homozygous ( Fig. S13A and S13B in the Supplementary Appendix). Immunohistochemical analysis for MHC class I heavy chains revealed loss of outer-membrane localization as compared with adjacent stroma or the baseline tumor, even though diffuse intracellular staining indicated continued production of MHC class I molecules (Fig. S14 in the Supplementary Appendix). This finding is in line with the role of beta-2-microglobulin in proper MHC class I folding and transport to the cell surface, and its deficiency has long been recognized as a genetic mechanism of acquired resistance to immunotherapy. [12] [13] [14] Both the baseline and relapse biopsy samples were negative for MHC class II expression (Fig. S14 in the Supplementary Appendix), which suggests a lack of compensatory MHC up-regulation.
We could not find defined genetic alterations in Patient 4 that had clear potential to result in acquired resistance to T cells, but cancer cells in the baseline and relapse biopsy samples did not express PD-L1 despite proximity to T cells and PD-L1-expressing stroma (Fig. S3D in the Supplementary Appendix). These findings suggest possible nongenetic mechanisms of altered expression of interferon-inducible genes. 16 
Discussion
With the approval of PD-1 checkpoint-blockade agents for the treatment of patients with melanoma, lung cancer, and other cancers, it is anticipated that cases of late relapse after initial response will increase. Understanding the molecular mechanisms of acquired resistance by focused comparison of biopsy samples from paired baseline and relapsing lesions may open options for the rational design of salvage combination therapies or preventive interventions and may guide mechanistic biomarker studies for the selection of patients, before the initiation of treatment, who are unlikely to have a response.
Tumor-infiltrating T cells are the effectors that kill cancer cells during PD-1 blockade therapy. 19, 31 We found it striking that after intratumoral CD8 T-cell infiltration during active response, CD8 T cells were usually still present and abundant at the time of relapse, though they were restricted to the tumor margin. This observation suggested to us that the T cells were no longer able to exert their cytotoxic activity, because of either a lack of tumor antigen recognition and activation or a loss of sensitivity to their effector molecules by the cancer cells. The gen- Figure 4 (facing page) . Loss of Interferon Gamma-Induced Growth Arrest through Acquired JAK Mutations.
In Panel A, the M407 parental cell line as well as the M407 JAK1-knockout and JAK2-knockout sublines were recognized by NY-ESO-1-specific, HLA-A*02:01-restricted T cells, as assessed by interferon-γ production after 24 hours of in vitro coculture. M420 is negative for HLA-A*02:01 and served as a negative control. In Panel B, cell lines M420 and M407 showed growth inhibition in response to direct in vitro treatment with interferon alfa, beta, or gamma (left), whereas the JAK2-deficient counterpart M464 and the M407 JAK2 knockout were insensitive specifically to interferon gamma (middle). The M407 JAK1 knockout was insensitive to all three interferons (right). In Panel C, treatment with 2′3′-cGAMP (cyclic guanosine monophosphate-adenosine monophosphate), a direct cytosolic agonist of the stimulator of interferon genes (STING), was able to produce growth arrest in all cell lines, regardless of JAK2 status, yet had no effect in M407 with JAK1 knockout. eral possibilities are loss of mutational or shared tumor antigens that are recognized by T cells, loss of antigen-presenting machinery components (e.g., beta-2-microglobulin and HLA), [12] [13] [14] tumorcell-induced or myeloid-cell-induced inactivation of T-cell signaling, 32, 33 or insensitivity to the proapoptotic effects of toxic granules (e.g., perforin and granzymes), death receptors (e.g., Fas and tumor necrosis factor-related apoptosisinducing ligand [TRAIL]), or interferons. 34 Any of these escape mechanisms would be hypothesized to be fostered by the selective pressure of CD8 attack, which would be particularly active during the new round of immunoediting 35 that is unleashed after PD-1 blockade.
The inactivation of JAK1 or JAK2, as noted in two of the patients, may be particularly advantageous to cancer cells in the context of anti-PD-1 therapy as compared with other immunotherapies. The interferon-induced adaptive expression of PD-L1, which allows the cancer to inactivate adjacent CD8 T cells, 36 would be of no use after the PD-1-PD-L1 interaction is blocked by therapeutic antibodies. We propose that without this benefit, the advantage for cancer cells tilts toward abolishing interferon signaling in order to avoid the detrimental increase in antigen presentation and direct antiproliferative effects. 27 Although we identified inactivating mutations in JAK1 and JAK2, which are receptor-level signaling bottlenecks, interferon insensitivity through other means -such as epigenetic silencing of interferon-signaling components as previously documented in lung-cancer and prostate-cancer cell lines 15, 16 or increased expression of negative regulators 37 -might lead to the same end. We also documented one case of beta-2-microglobulin inactivation, which corroborates a previously described mechanism of acquired resistance to cancer immunotherapy in humans through loss of this shared component of all human MHC class I molecules that is required for CD8 T-cell recognition. [12] [13] [14] In conclusion, the nearly identical mechanism of acquisition, functional consequence, and evidence of clonal selection for JAK1 or JAK2 mutations in two independent cases with a similar clinical course of acquired resistance suggests that resistance to interferon gamma contributes to immune resistance and escape. This genetic alteration of immune resistance joins the previously described loss of B2M in decreasing immune-cell recognition of cancer cells, leading to acquired resistance to cancer immunotherapy. Although we have identified four cases and worked out a potential mechanism of resistance in three of them, additional cases will need to be closely examined to assess the generalizability of these findings.
